GlucoTrack Shares Surged After Partnership Deal

Lokahi Therapeutics signed a fee-for-service agreement to aid Innovate GBM with brain tumor asset identification.

Updated on Sept. 24, 2026 in Healthcare

Isometric editorial illustration of a complex molecular model representing a pharmaceutical compound, rendered in matte geometric shapes. — GlucoTrack shares rose 80% on Wednesday after subsidiary Lokahi Therapeutics announced a fee-for-service partnership to support Innovate GBM's brain tumor research. AI Illustration. Upload story photo >

Live Poll

Do you generally trust the long-term potential of small-cap biotech stocks after market-moving news?

GlucoTrack shares saw an 80.30% increase in after-hours trading on Wednesday following news that its subsidiary, Lokahi Therapeutics, inked a partnership deal with Innovate GBM. The deal marks the first time an external organization will utilize Lokahi's proprietary AI asset-identification pipeline.

Why it matters

Innovate GBM aims to utilize the AI-driven pipeline, which incorporates data from 14 university collaborations, to find a more capital-efficient method for discovering overlooked therapeutic assets for brain tumors. The agreement allows Innovate GBM to independently determine whether it will pursue any assets identified through the project teams.

GlucoTrack shares rose to $3.66 in after-hours trading, bringing the trading volume to 27.58 million shares against a 1.34 million average. The company currently holds a market capitalization of $1.62 million.

The players

GlucoTrack

A New Jersey-based company that operates through subsidiaries including Lokahi Therapeutics.

Lokahi Therapeutics

A subsidiary of GlucoTrack that manages an AI-driven pipeline for identifying therapeutic assets.

Innovate GBM

An organization focused on the development of brain tumor treatments that has partnered with Lokahi Therapeutics.

The details

Innovate GBM has engaged two AI pipeline project teams from Lokahi Therapeutics to assist in searching for new brain tumor treatments. This collaboration represents the first instance of Lokahi's internal asset-identification process being opened to an external entity.

The regular trading session closed at $2.03 on September 23, 2026.
After-hours stock price surge occurred on September 23, 2026.

Market Landscape

This deal underscores a broader push toward leveraging specialized AI platforms to streamline R&D within the highly competitive oncology sector. It positions GlucoTrack to monetize its proprietary identification processes by providing services to external firms navigating the capital-intensive drug search market.

The volatility in GlucoTrack stock prices may impact retail investors who hold positions in the company or are monitoring its recovery from a 97.64% price decline. The partnership does not immediately change product availability or pricing for the average patient or consumer.

The takeaway

Investors should note that while this partnership signals technical progress for the subsidiary, the company's long-term financial health remains tied to the success of its AI-driven identification model. The deal provides a new operational revenue stream but does not guarantee the discovery of viable new therapies.